• Vor Bio, a developer of CRISPR-aided stem cell therapies, is laying off 95% of its workforce.
• The company is winding down both its clinical and manufacturing operations.
• The cuts represent a major strategic retreat amid broader biotech sector challenges.
• Vor had focused on developing genetically engineered stem cell transplants for cancer treatment.
There are no replies in this thread yet. Be the first to post a reply below: